Differential expression of SHP-1 in chronic myeloid leukemia

DISCLAIMER: The ideas and opinions expressed in the journal’s Just Accepted articles do not necessarily reflect those of Informa Healthcare (the Publisher), the Editors or the journal. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in these articles. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosages, the method and duration of administration, and contraindications. It is the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Just Accepted articles have undergone full scientific review but none of the additional editorial preparation, such as copyediting, typesetting, and proofreading, as have articles published in the traditional manner. There may, therefore, be errors in Just Accepted articles that will be corrected in the final print and final online version of the article. Any use of the Just Accepted articles is subject to the express understanding that the papers have not yet gone through the full quality control process prior to publication. Just Accepted by Leukemia & Lymphoma

[1]  M. Caligiuri,et al.  PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. , 2013, The Journal of clinical investigation.

[2]  H. Kantarjian,et al.  Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. , 2013, Clinical lymphoma, myeloma & leukemia.

[3]  Catriona H. M. Jamieson,et al.  Chronic Myeloid Leukemia Stem Cell Biology , 2012, Current Hematologic Malignancy Reports.

[4]  J. Radich,et al.  SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. , 2011, Blood.

[5]  G. Garcia-Manero,et al.  Decreased expression level of SH2 domain‐containing protein tyrosine phosphatase‐1 (Shp1) is associated with progression of chronic myeloid leukaemia , 2007, The Journal of pathology.

[6]  D. Marin,et al.  Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. , 2006, Blood.

[7]  Guido Marcucci,et al.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. , 2005, Cancer cell.

[8]  Susan Branford,et al.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. , 2003, The New England journal of medicine.

[9]  U. Lorenz,et al.  Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation , 2001, Leukemia.